KRAS and neoplasm: Together, these studies show that sustained engagement of the IL-1/Toll-like receptors not only propels malignant progression of KRAS-mutant pre-cancerous cells through amplifying tumor-intrinsic signaling and modulating extrinsic immune cells, but also contributes to treatment resistance of fully-transformed PDAC cells.